top of page
Search

Prostate Disease in Older Adults: Early Recognition, Evidence-Based Management, and What Clinicians Need to Know

Prostate disease, particularly prostate cancer and benign prostatic hyperplasia (BPH), remains one of the most pressing urologic issues in aging men. As a central topic in the 41st Annual UCLA Intensive Course in Geriatric Medicine & Board Review, understanding the latest science and applying it in clinical settings is critical for improving outcomes.


Understanding the Causes of Prostate Cancer

Prostate cancer is multifactorial in origin, with age, genetics, race, and hormonal factors being the leading contributors. The risk of developing prostate cancer increases substantially with age more than 60% of cases are diagnosed in men over 65 (Siegel et al., 2024).


Key contributing factors include:

  • Age: Aging is the strongest risk factor.

  • Genetics: Men with a first-degree relative with prostate cancer are 2 to 3 times more likely to develop the disease (Carter et al., 1992).

  • Race: Black men are at significantly higher risk and have worse outcomes.

  • Hormonal Influence: Elevated lifetime exposure to androgens may promote carcinogenesis, although the role of testosterone remains complex (Hsing et al., 2000).

  • Diet and Inflammation: High intake of red meat and high-fat dairy, along with chronic inflammation, may contribute to increased risk (World Cancer Research Fund/AICR, 2018).


Recognizing the Symptoms: Subtle but Significant

Early-stage prostate cancer often presents without symptoms, making screening essential in appropriate populations. When symptoms occur, they can resemble benign conditions like BPH, including:

  • Frequent urination (especially at night)

  • Hesitancy or difficulty starting urination

  • Weak or interrupted urine stream

  • Painful urination or ejaculation

  • Blood in urine or semen

Advanced disease may present with bone pain, weight loss, or lower extremity weakness due to metastases.


Early Detection and Intervention: What the Evidence Says

While prostate-specific antigen (PSA) screening has been controversial, recent guidelines emphasize shared decision-making. According to the U.S. Preventive Services Task Force (USPSTF), men aged 55–69 should discuss the benefits and risks of screening with their clinicians, while routine screening is not recommended in men over 70 (USPSTF, 2018).


Early intervention may include:

  • Active surveillance for low-risk disease

  • Surgical or radiation therapy for localized cancer

  • Androgen deprivation therapy (ADT) for advanced disease

  • Multidisciplinary management involving urology, oncology, and geriatrics


What Clinicians Should Prioritize

Given the complexity of aging patients, clinicians must be prepared to interpret PSA values in context, identify red flags for referral, and navigate treatment decisions tailored to both frail and robust older adults. Ethical considerations, especially when screening high-risk or medically complex individuals, require thoughtful, individualized care planning.

Providers should stay up to date on:

  • Age-adjusted PSA guidelines

  • Risk factors that warrant earlier or more aggressive evaluation

  • When to consider active surveillance vs. intervention

  • Patient-centered conversations that align treatment with values, quality of life, and prognosis.


A Call to Action

With a rapidly aging population and the high prevalence of prostate conditions, it is essential that clinicians across specialties remain vigilant. Timely recognition, evidence-based evaluation, and appropriate intervention can significantly impact outcomes and preserve quality of life.

Whether in primary care, geriatrics, or specialty practice, the role of the clinician is not just to diagnose, but to advocate, educate, and act early.

 

Interested in learning more about clinical decision-making in geriatrics?

Explore evidence-based updates, real-world case discussions, and tools to sharpen your diagnostic approach to older adults. Click below to view the upcoming intensive learning opportunity.




References:

Siegel, R.L., Miller, K.D., Wagle, N.S., & Jemal, A. (2024). Cancer Statistics, 2024. CA: A Cancer Journal for Clinicians, 74(1), 7–33.


Carter, B.S., et al. (1992). Hereditary prostate cancer: Epidemiologic and clinical features. The Journal of Urology, 147(5), 1290–1294.


Hsing, A.W., Chokkalingam, A.P. (2000). Prostate cancer epidemiology. Frontiers in Bioscience, 5, d820–d833.


U.S. Preventive Services Task Force (USPSTF). (2018). Screening for Prostate Cancer: Recommendation Statement. JAMA, 319(18), 1901–1913.


World Cancer Research Fund/American Institute for Cancer Research. (2018). Diet, Nutrition, Physical Activity and Prostate Cancer. www.wcrf.org


 

bottom of page